drugset / Trial / NCT02269488
A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years
Non-randomizedSingle-groupOpen-labelPrevention
Summary
This open-label, single arm, multicenter study will enroll approximately 100 subjects. The study is designed to gather the safety and tolerability data in Japanese children 2 to 6 years of age that would support approval of MEDI3250 in Japan.
Timeline
- Start
- 2014-11
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MEDI3250 | Vaccine | 0.2 ml | Intranasal |
Indications
No indication recorded.